Objectives: Large population-based registries in Western countries show that the treatment strategy for glioblastoma multiforme (GBM) in elderly patients is likely less intensive. The purpose of this study was to clarify the treatment outcome of elderly patients with GBM and to explore appropriate treatment strategies.
G lioblastoma multiforme (GBM) is the most common glioma, occurring more often in patients in their 60s and 70s. 1, 2 GBM is a rapidly progressive brain tumor, and the standard of care includes surgery, postoperative radiotherapy, and systemic chemotherapy. 1, [3] [4] [5] [6] In most clinical trials, the optimal treatment has been offered to only a selected subgroup of patients with GBM, such as those aged <70 years and with a good performance status (PS). 4, 7 There is little information to define the standard of care for elderly patients with GBM. 6, 8, 9 Large population-based cancer registries in Western countries show that the treatment strategy for GBM in patients aged >70 years is likely to be less intensive and more palliative. 1, 10 Data from the United States National Cancer Institute's Surveillance, Epidemiology, and End Results program showed that a total of 1412 patients with GBM (35%) received neither radiation nor chemotherapy, and patients who were elderly, unmarried, or had more comorbidities were less likely to receive radiotherapy and chemotherapy. 10, 11 The cancer registry in Switzerland showed that although 56% of patients with GBM, aged 65 to 74 years, underwent surgery followed by radiotherapy, radiotherapy alone, or surgery alone, only 25% of the patients aged >75 years underwent surgery and/or radiotherapy. 12 Some retrospective studies have shown that aggressive treatment is associated with prolonged survival in elderly patients with GBM. A study at the Memorial Sloan-Kettering Cancer Center demonstrated that, similar to studies in younger patients with GBM, age, PS, and extension of surgery were independent prognostic factors for treatment outcome of elderly patients, and emphasized that age alone should not disqualify patients from aggressive-combined treatment. 10 Results from the Cleveland Clinic showed that elderly patients aged >70 years with good PS, treated aggressively with maximal resection and definitive radiotherapy survived longer than those who received palliative radiotherapy and biopsy. 8 More prospective and retrospective studies are needed to establish the standard of care for elderly patients with GBM.
The purpose of this retrospective study was to clarify the treatment outcome of patients with GBM aged >70 years who received combination therapy, and to explore appropriate treatment strategies for elderly patients.
MATERIALS AND METHODS
We analyzed records from 86 patients (median age, 59 y; range, 9 to 77 y) who were diagnosed and histologically confirmed to have GBM between January 1991 and June 2006 at our institutions. Fourteen patients were aged >70 years (elderly patients; range, 71 to 77 y) and 72 patients were aged r70 years (younger patients; range, 9 to 70 y). Forty-six patients (53%) had good PS scores (0 to 1), whereas 40 (47%) had poor PS scores (2 to 4). The median preoperative tumor size was 4.5 cm (range, 1.4 to 8 cm; Table 1 ). Fifty-two patients (60%) underwent total or subtotal resection, and 34 (40%) underwent partial resection or biopsy. There was no difference in extension of surgery between elderly and younger patients (P = 0.55). O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation status was not assessed in all patients.
Radiotherapy started within 6 weeks postoperatively. As a basic procedure, clinical target volume was based on preoperative computed tomography (CT) and magnetic resonance imaging (MRI) studies, and included the enhanced tumor and peritumoral edema with 1.5 to 2 cm margins. The planning target volume (PTV) was based on clinical target volume with a 0.5 cm margin. If the PTV included critical organs, such as the brainstem, optic chiasm, optic nerve, or retina, PTV was reduced to a 1 to 1.5 cm margin of the preoperative gross tumor volume after a radiation dose of 50 Gy. A photon energy of 4 MV, 6 MV, or 10 MV was used. Treatment plans included lateral-opposed fields, wedged-pair fields, rotation techniques, or multiple-field techniques. Computer-aided treatment planning was performed after the late 1990s. The prescribed dose was calculated at the center of the radiation field or that of the PTV. A 74-year-old man with poor PS, who was grouped into class 6 by recursive partitioning analysis (RPA), was treated with 30 Gy in a fraction size of 3 Gy over 2 weeks. The remaining 85 patients were treated with 42 to 70 Gy in a fraction size of 1.8 to 2 Gy over 4 to 7 weeks. The median and mean radiation doses were 60 and 55 Gy (range, 30 to 70 Gy) in elderly patients, and 54 and 54 Gy (range: 42 to 66 Gy) in younger patients. There was no difference between the total radiation dose in elderly and younger patients (P = 0.22).
Seventy-nine patients (92%) received anticancer agents, including cytotoxic agents and/or interferon-b, during or after radiotherapy. Sixty-nine younger patients (96%) and 10 elderly patients (71%; P=0.008) received anticancer agents. Nitrosourea alone or nitrosourea-containing combination chemotherapy was administered to 75 patients, usually concomitant with radiotherapy and/or in a postradiotherapy adjuvant setting. Seventy patients received intravenous interferon-b at a dose of 3,000,000 IU daily during radiotherapy and weekly in a postradiotherapy adjuvant setting. As a basic procedure, patients received these anticancer agents until disease progression or development of severe adverse events. Temozolomide, an oral alkylating agent, was not used in the initial treatment of all patients. Temozolomide was approved for clinical use by the Ministry of Health, Labor, and Welfare of Japan in July 2006. Only a 59-year-old man, who was grouped into RPA class 4, was treated with temozolomide after local progression.
Overall survival time and progression-free survival (PFS) was measured from the date of treatment initiation. PFS was calculated using disease progression and death due to any cause such as events, and overall survival was calculated using death due to any cause such as an event. Disease progression was defined as an increase in tumor size compared with the initial tumor volume visualized on CT/MR images or the appearance of a new lesion separate from the initial tumor volume. Local progression was defined as a tumor size increase or new lesion in the surgical cavity seen on CT/MR images, and distant progression was defined as the appearance of new lesions separated from the initial tumors by at least 2 cm on CT/MR images. We used the Kaplan-Meier method to estimate survival distributions for each group and the log-rank test to compare survival distributions using a significance level of <0.05. The Mantel-Haenszel w 2 test was used to compare patients and tumor characteristics at baseline. We carried out a multivariate analysis of prognostic factors using the Cox proportional hazards model. Statistical analysis was carried out using JMP version 5.1J (SAS Institute Inc.).
RESULTS
The median follow-up for all patients was 11.6 months (range, 1.4 to 105.8 mo). The median PFS and median survival time (MST) of all 86 patients were 5.8 months [95% confidence interval (CI), 4.7-7.4] and 12.8 months (95% CI, 10.8-14.9), respectively. One-year and 2-year overall survival rates of all patients were 53% and 16%, respectively. Thirteen patients (15%) showed disease progression at the end of radiotherapy. Twelve younger patients (17%) and 1 elderly patient (7%) showed local progression at the end of radiotherapy (P=0.36). The MST of the 35 patients in classes 3 and 4 was 16.9 months (95% CI, 14.2-22.7), and that of the 51 patients in classes 5 and 6 was 11.0 months (95% CI, 9.3-12.6; P < 0.001; Fig. 1 ).
Among the patients in classes 3 and 4, the MST of 2 elderly patients was 14.8 months (95% CI, 10.5-N/A), and that of 33 younger patients was 18.1 months (95% CI, 14.2-24.4; Fig. 2 ). The 2-year overall survival rates of elderly and younger patients in classes 5 and 6 were 0% and 9%, respectively. The MST of the 20 middle-aged patients (61 to 70 y) in classes 5 and 6 was 8.8 months (95% CI, 6.7-12.0), and the 2-year overall survival rate was 0%. There was no difference between the MST of middle-aged patients and that of elderly patients (>70 y) (P = 0.48). The median PFS of elderly patients in classes 5 and 6 was 5.3 months (95% CI, 1.1-9.4), and that of younger patients was 5.8 months (95% CI, 3.2-7.2; P = 0.74). The median PFS of middle-aged patients in classes 5 and 6 was 3.6 months (95% CI, 1.7-7.2), and there was no difference between that of the middle-aged patients and that of elderly patients (P = 0.70). Among patients in classes 5 and 6, there was no difference between the extension of surgery and total radiation dose between elderly and younger patients (P = 0.36 and 0.69). However, younger patients received anticancer agents more frequently than elderly patients (P = 0.03). We carried out a multivariate analysis including RPA class (3 to 4 vs. 5 to 6), age (60 to 70 y vs. >70 y), total radiation dose, and treatment with anticancer agents (yes vs. no). Only RPA class was an independent prognostic factor for overall survival rate (P = 0.009), whereas age (P = 0.85), total radiation dose (P=0.052), and treatment with anticancer agents (P = 0.32) were not. We also carried out a multivariate analysis including these prognostic factors for PFS, but found no independent prognostic factors (RPA classes, P=0.67; age, P = 0.25; total radiation dose, P = 0.11; anticancer agents, P = 0.13).
Sixty-five patients (75%) showed disease progression during the follow-up period: 54 patients (83%) had local progression, 8 (12%) had both local and distant progression, and 3 (5%) had only distant progression. Salvage therapies, including chemotherapy or best supportive care (BSC), were performed according to each physician's policy.
DISCUSSION
Data from the cancer registry in Switzerland demonstrated that 27% of patients with GBM aged 55 to 64 years, 44% of the patients aged 65 to 74 years, 75% of the patients aged >75 years received BSC alone without effective treatment. 12 The Surveillance, Epidemiology, and End Results-Medicare linked data demonstrated that increased age was associated with noneffective treatment and hence, worse prognosis. 13 Although these large population-based cancer registries demonstrate that an increase in age is associated with less intensive treatment, there is little information to define the standard of care for elderly patients with GBM. 9 In particular, there are no prospective randomized studies that evaluate the effectiveness and safety of combination therapy, including postoperative radiotherapy and chemotherapy, for patients aged Z70 years.
Adjuvant systemic chemotherapy after surgery prolongs survival in patients with GBM. 6, 14 A meta-analysis of 12 randomized controlled trials, including more than 3000 patients, compared postoperative radiotherapy alone with postoperative radiotherapy and chemotherapy, and demonstrated that the addition of chemotherapy decreased the risk of death by 15% (hazard ratio, 0.85; 95% CI, 0.78-0.91). 5 The European Organisation for Research and Treatment of Cancer/the National Cancer Institute of Canada Intergroup conducted a randomized clinical trial for patients aged 18 to 70 years with newly diagnosed GBM, and reported that the 2-year survival rate was 26% for the temozolomide and radiotherapy group compared with only 10% for the radiation only group. 4 This trial demonstrated the clinical benefit of temozolomide in patients with GBM, but subset analysis showed that the benefit was not statistically significant in patients undergoing diagnostic biopsy only or those with poor PS. 4, 15 The 5-year analysis of this trial demonstrated that patients aged 60 to 70 years benefited from combined therapy (hazard ratio for overall survival, 0.7; range, 0.5 to 0.97). 16 Grant et al 17 retrospectively analyzed 148 patients with malignant gliomas or recurrent astrocytomas who received nitrosourea-based chemotherapy, and reported that age was strongly predictive of the likelihood of responding to chemotherapy, time to progression, and survival, and patients aged Z60 years had a lower chance of benefiting from chemotherapy. On the other hand, Combs et al 18 conducted a retrospective study including 43 patients aged Z65 years (range, 65 to 76 y) who received postoperative radiotherapy and chemotherapy, and reported that radiochemotherapy was safe and effective in this population. Prospective studies are required to clarify the benefit of chemotherapy for elderly patients with GBM.
The Medical Research Council conducted a randomized trial comparing 45 Gy in 20 fractions over 4 weeks with 60 Gy 20 conducted a prospective randomized trial that compared standard radiation therapy (60 Gy in 30 fractions over 6 wk) and a short course of radiotherapy (40 Gy in 15 fractions over 3 wk) in patients aged Z60 years. There was no difference in survival between the 2 groups, and short-course radiotherapy led to a decrease in posttreatment corticosteroid dosage. Although radiotherapy has been effective and safe in elderly patients, it is unclear whether a total dose of 60 Gy represents the standard dose for these patients. 6, 19 A limitation of this study is that the median radiation dose for younger patients was <60 Gy. However, there was no statistical difference between the radiation dose in elderly, middle-aged, and younger patients and multivariate analysis showed that total radiation dose was not associated with overall survival. This study is also limited due to the lack of evaluation of MGMT methylation status, quality of life, and long-term neurotoxicity.
Although age is an important factor for predicting survival of patients with GBM, there is a room for discussion as to whether less intensive therapy is suitable for the majority of elderly patients. 8, 9 RPA proposed by the Radiation Therapy Oncology Group has been a useful tool for predicting the prognosis of patients with malignant glioma. 21 RPA includes age, histology, mental status, PS, and the extent of surgical excision. The median survival time was 4.7 to 58.6 months for the 12 subgroups resulting from this analysis. This study showed that the MST of the 35 patients in classes 3 and 4 was superior to that of 51 patients in classes 5 and 6 (P < 0.001). However, a limitation of the RPA classification is that it requires the extent of surgical excision, which cannot be assessed before treatment, and this prognostic system is not used for the initial pretreatment decision-making process. The Organisation for Research and Treatment of Cancer/the National Cancer Institute of Canada Clinical Trials Group developed nomograms for predicting survival in patients with GBM. The nomograms include methylated MGMT promoter status, age, PS, extension of surgical excision, and Mini-Mental State Examination score. 7 Patients with GBM with a methylated MGMT promoter benefit from temozolomide and have a good prognosis. 22 This additional molecular information may be useful for estimating the treatment outcome of patients with GBM, and other molecular characteristics and predictive markers may facilitate individually tailored therapy.
In this study, the majority of elderly patients were grouped in RPA classes 5 and 6. However, an analysis adjusting for RPA classification showed that the treatment outcome of patients aged >70 years in classes 5 and 6 and that of younger patients in classes 5 and 6 was likely to be equal. Treatment decision-making should be performed in the same manner in elderly patients as for younger patients, and definitive treatment should not be withheld based on age alone.
